Copyright
©The Author(s) 2022.
World J Clin Pediatr. Jul 9, 2022; 11(4): 341-350
Published online Jul 9, 2022. doi: 10.5409/wjcp.v11.i4.341
Published online Jul 9, 2022. doi: 10.5409/wjcp.v11.i4.341
Table 3 Data on the use of biological therapy in patients with inflammatory bowel disease pediatric and adults, in the state of Espírito Santo, August 2012 to July 2014
| Biological | Total amount | Age at diagnosis ≤ 17 yr old | Age at diagnosis > 18 yr old | P value | |||
| n | % | n | % | n | % | ||
| 1.048 | (100) | 55 | (5.24) | 993 | (94.76) | ||
| IBD | 187 | (17.8) | 19 | (34.5) | 168 | (16.9) | P = 0.001 |
| CD | 155 | (43.5) | 17 | (56.7) | 138 | (42.2) | P = 0.126 |
| UC | 30 | (4.5) | 2 | (8.3) | 28 | (4.3) | P = 0.353 |
- Citation: Martins AL, Fróes RSB, Zago-Gomes MP. Prevalence, phenotype and medication for the pediatric inflammatory bowel disease population of a state in Southeastern Brazil. World J Clin Pediatr 2022; 11(4): 341-350
- URL: https://www.wjgnet.com/2219-2808/full/v11/i4/341.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v11.i4.341